About Journal of Experimental & Clinical Cancer Research

What is Journal of Experimental & Clinical Cancer Research?

Journal of Experimental & Clinical Cancer Research (JECCR), the official journal of the "Regina Elena" National Cancer Institute, is an open access publication providing a high-quality forum for basic, clinical and translational work in oncology.

The journal publishes scientific studies on the immunological, epidemiological, pathological, biological and clinical aspects of oncology. Topics considered range from molecular genetics via infectious agents to surgery and therapeutic approaches and outcomes. Systematic reviews of clinical and basic research, as well as clinical practice guidelines, are especially welcome.

An established journal published since 1982, JECCR is tracked/indexed by Thomson Reuters, Medline, Embase and CAS. To browse articles published in the journal prior to its move to BioMed Central click here.

Content overview

Journal of Experimental & Clinical Cancer Research considers the following types of article:

• Research: reports of data from original research.
• Reviews: comprehensive, authoritative, descriptions of any subject within the scope of the journal. These articles are usually written by opinion leaders that have been invited by the Editorial Board.
• Case reports: reports of clinical cases that can be educational, describe a diagnostic or therapeutic dilemma, suggest an association, or present an important adverse reaction. All case report articles should indicate that informed consent to publish the information was granted from the patients or their guardians.
• Case studies: descriptions of a major healthcare intervention, usually from a public health perspective. Case study articles should include a rigorous assessment of the processes and impact of the intervention as well as recommendations for future interventions.

Peer review policies

Journal of Experimental & Clinical Cancer Research has a ‘closed’ peer review policy. After an initial screening for general suitability, new submissions will be sent to at least two recognised experts in the field for peer review. In cases of conflicting reports a third reviewer will be consulted, but final decisions will rest with the Editor-in-Chief. The journal aims to provide authors with a first decision (accepted/rejected/revisions needed) within six weeks.

Where authors are unhappy about decisions, the Editor-in-Chief and the Regional Editors will discuss the situation. Should there be at least one Editor in favor of reconsideration, the authors will be offered another round of peer review.

Edited by Mauro Castelli, Journal of Experimental & Clinical Cancer Research is supported by an international Editorial Board.

Publishing in Journal of Experimental & Clinical Cancer Research

All articles will be listed in PubMed immediately upon acceptance (after peer review), and will be covered by PubMed Central, MEDLINE, Thomson Reuters (ISI) and CAS.

Articles in Journal of Experimental & Clinical Cancer Research should be cited in the same way as articles in a traditional journal. However, because articles in this journal are not printed, they do not have page numbers. Instead, they have a unique article number.

The following citation:

J Exp Clin Cancer Res 2004, 2:1

refers to article 1 from volume 2 of the journal.

As an online journal, Journal of Experimental & Clinical Cancer Research does not have issue numbers. Each volume corresponds to a calendar year.

To keep up to date with the latest articles from Journal of Experimental & Clinical Cancer Research, why not register to receive alerts? Registration also enables you to customise your subject areas of interest, store your searches, and submit your manuscripts.

Submission of manuscripts

Manuscripts should be submitted electronically to Journal of Experimental & Clinical Cancer Research using the online submission system. Full details of how to submit a manuscript are given in the instructions for authors.

General journal policies

Journal of Experimental & Clinical Cancer Research is published by BioMed Central, an independent publisher committed to ensuring peer-reviewed biomedical research is Open Access. That means it is freely and universally accessible online, it is archived in at least one internationally recognised free access repository, and its authors retain copyright, allowing anyone to reproduce or disseminate articles, according to the BioMed Central copyright and licence agreement. Journal of Experimental & Clinical Cancer Research however, has taken this further by making all its content Open Access.

Journal of Experimental & Clinical Cancer Research's articles are archived in PubMed Central, the US National Library of Medicine's full-text repository of life science literature, and also in repositories at the University of Potsdam in Germany, at INIST in France and in e-Depot, the National Library of the Netherlands' digital archive of all electronic publications. The journal is also participating in the British Library's e-journals pilot project, and plans to deposit copies of all articles with the British Library.

BioMed Central is working closely with the Thomson Reuters (ISI) to ensure that citation analysis of articles published in Journal of Experimental & Clinical Cancer Research will be available.

Journal of Experimental & Clinical Cancer Research is able to deliver summaries of frequently updated content via Really Simple Syndication (RSS) feeds. These are accessible via the orange "XML" button at the top of the list of recent articles or the list of most accessed articles. For more information about RSS feeds see our publisher's website.

For further information about general policies please see the instructions for authors.